TIL vs. ABUS, EOLS, UPB, XNCR, SAGE, KALV, DNTH, RLAY, IOVA, and AMLX
Should you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Arbutus Biopharma (ABUS), Evolus (EOLS), Upstream Bio (UPB), Xencor (XNCR), Sage Therapeutics (SAGE), KalVista Pharmaceuticals (KALV), Dianthus Therapeutics (DNTH), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry.
Instil Bio vs. Its Competitors
Arbutus Biopharma (NASDAQ:ABUS) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.
Arbutus Biopharma has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Instil Bio has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500.
Instil Bio has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,196.64%. Instil Bio's return on equity of -45.52% beat Arbutus Biopharma's return on equity.
43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 20.3% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 47.2% of Instil Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Arbutus Biopharma has higher revenue and earnings than Instil Bio. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.
Arbutus Biopharma presently has a consensus target price of $5.50, indicating a potential upside of 70.02%. Instil Bio has a consensus target price of $119.00, indicating a potential upside of 321.54%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than Arbutus Biopharma.
In the previous week, Instil Bio had 4 more articles in the media than Arbutus Biopharma. MarketBeat recorded 5 mentions for Instil Bio and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.00 beat Instil Bio's score of -0.07 indicating that Arbutus Biopharma is being referred to more favorably in the media.
Summary
Instil Bio beats Arbutus Biopharma on 10 of the 15 factors compared between the two stocks.
Get Instil Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Instil Bio Competitors List
Related Companies and Tools
This page (NASDAQ:TIL) was last updated on 7/4/2025 by MarketBeat.com Staff
Free TIL Stock Alerts